Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed скачать в хорошем качестве

Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed

Call it fortuitous, good planning, instinct, or a combination of all three, but Nadim Ahmed's educational foundation— earned before the IT/Biology combination was cool— is serving him well as CEO at Cullinan Oncology. On this episode of the Business of Biotech, Ahmed shares his story and that of Cullinan Oncology's drug discovery efforts, which have yielded a wide range of multi-modal candidates spanning a range of cancer indications. Our discussion digs into the company's transition from R&D to the clinic, how its built an uncommonly comfortable cash position through partnership, and its ambition to become a fully-integrated commercial-stage biotech. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Get notified when new episodes come out: https://www.bioprocessonline.com/bob Audio version available here: https://www.bioprocessonline.com/doc/... Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast... Spotify - https://open.spotify.com/show/5NhjpDe... Google - https://podcasts.google.com/?q=busine...